Advertisement

Current Hypertension Reports

, Volume 15, Issue 3, pp 175–181 | Cite as

Potential Role of Uric Acid in Metabolic Syndrome, Hypertension, Kidney Injury, and Cardiovascular Diseases: Is It Time for Reappraisal?

  • Zohreh SoltaniEmail author
  • Kashaf Rasheed
  • Daniel R. Kapusta
  • Efrain Reisin
Hypertension and Obesity (E Reisin, Section Editor)

Abstract

Elevated serum uric acid concentration is a common laboratory finding in subjects with metabolic syndrome/obesity, hypertension, kidney disease and cardiovascular events. Hyperuricemia has been attributed to hyperinsulinemia in metabolic syndrome and to decreased uric acid excretion in kidney dysfunction, and is not acknowledged as a main mediator of metabolic syndrome, renal disease, and cardiovascular disorder development. However, more recent investigations have altered this traditional view and shown, by providing compelling evidence, to support an independent link between hyperuricemia and increased risk of metabolic syndrome, diabetes, hypertension, kidney disease and cardiovascular disorders. However, despite these new findings, controversy regarding the exact role of uric acid in inducing these diseases remains to be unfolded. Furthermore, recent data suggest that the high-fructose diet in the United State, as a major cause of hyperuricemia, may be contributing to the metabolic syndrome/obesity epidemic, diabetes, hypertension, kidney disease and cardiovascular disorder. Our focus in this review is to discuss the available evidence supporting a role for uric acid in the development of metabolic syndrome, hypertension, renal disease, and cardiovascular disorder; and the potential pathophysiology mechanisms involved.

Keywords

Uric acid Hyperuricemia Fructose Metabolic syndrome Obesity Hypertension Kidney disease Cardiovascular disorder 

Notes

Acknowledgment

This work was supported by National Institutes of Health grants 8P20 GM103514 and P20 RR018766 (to Z. Soltani and D.R. Kapusta) and American Heart Association grant 12GRNT12060613 (to D.R. Kapusta).

Conflict of Interest

Z. Soltani declares that he has no conflict of interest.

Kashef Rasheed declares that he has no conflict of interest.

D.R. Kapusta declares that he has no conflict of interest.

E. Reisin declares that he has no conflict of interest.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34:78–84.PubMedCrossRefGoogle Scholar
  2. 2.
    Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19:640–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. Br Med J. 1973;1:449–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Johnson RJ et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis? Atherosclerosis. 2000;148:131–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Ph. 2007;293:C584–96.CrossRefGoogle Scholar
  7. 7.
    Corry DB et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26:269–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553–62.PubMedCrossRefGoogle Scholar
  9. 9.
    Ginsberg MH, Kozin F, O'Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J Clin Investig. 1977;60:999–1007.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakagawa T et al. Uric acid–a uremic toxin? Blood Purif. 2006;24:67–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Nakanishi N et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18:523–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Sundstrom J et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28–33.PubMedGoogle Scholar
  14. 14.
    De Leeuw PW et al. Prognostic significance of renal function in elderly patients with isolated Systolic hypertension: Results from the Syst-eur trial. J Am Soc Nephrol. 2002;13. doi: 10.1097/01.Asn.0000027871.86296.92.
  15. 15.
    Bickel C et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol. 2002;89:12–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Matsuura F et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabol Clin Exp. 1998;47:929–33.CrossRefGoogle Scholar
  17. 17.
    Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arterioscler Thromb Vasc Biol. 2005;25:1038–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008–11.PubMedCrossRefGoogle Scholar
  19. 19.
    Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Muscelli E et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996;9:746–52.PubMedCrossRefGoogle Scholar
  21. 21.
    Quinones Galvan A et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268:E1–5.PubMedGoogle Scholar
  22. 22.
    Sui X, Church TS, Meriwether RA, Lobelo F, Blair SN. Uric acid and the development of metabolic syndrome in women and men. Metabol Clin Exp. 2008;57:845–52.CrossRefGoogle Scholar
  23. 23.
    Ryu S et al. Incidence and risk factors for metabolic syndrome in Korean male workers, ages 30 to 39. Ann Epidemiol. 2007;17:245–52.PubMedCrossRefGoogle Scholar
  24. 24.
    Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31:361–2.PubMedCrossRefGoogle Scholar
  25. 25.
    Niskanen L et al. Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care. 2006;29:709–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Chen LY et al. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci. 2007;B8:593–8. doi: 10.1631/jzus.2007.B0593.Google Scholar
  27. 27.
    See LC et al. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate. J Rheumatol. 2009;36:1691–8. doi: 10.3899/jrheum.081199.PubMedCrossRefGoogle Scholar
  28. 28.
    Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013;25:210–6.PubMedCrossRefGoogle Scholar
  29. 29.
    •• Osgood K, Krakoff J, Thearle M. Serum Uric Acid Predicts Both Current and Future Components of the Metabolic Syndrome. Metab Syndr Relat Disord. 2013. doi: 10.1089/met.2012.0151. This study demonstrates that not only did uric acid associate with concomitant insulin action, lipids, and blood pressure, also predicts future declines in insulin action and T2DM.
  30. 30.
    Perheentupa J, Raivio K. Fructose-induced hyperuricaemia. Lancet. 1967;2:528–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Havel PJ. Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev. 2005;63:133–57.PubMedCrossRefGoogle Scholar
  32. 32.
    Teff KL et al. Endocrine and Metabolic Effects of Consuming Fructose- and Glucose-Sweetened Beverages with Meals in Obese Men and Women: Influence of Insulin Resistance on Plasma Triglyceride Responses. J Clin Endocr Metab. 2009;94:1562–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Nakagawa T et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Ren Physiol. 2006;290:F625–631. doi: 10.1152/ajprenal.00140.2005.CrossRefGoogle Scholar
  34. 34.
    Sanchez-Lozada LG et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Ren Physiol. 2008;294:F710–8.CrossRefGoogle Scholar
  35. 35.
    Khosla UM et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Mercuro G et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94:932–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Kanbay M et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clinical J Am Soc Nephrol. 2011;6:1887–94.CrossRefGoogle Scholar
  39. 39.
    Yelken B et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol. 2012;77:275–82.PubMedGoogle Scholar
  40. 40.
    Ho WJ et al. Association between endothelial dysfunction and hyperuricaemia. Rheumatology. 2010;49:1929–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. American journal of physiology. J Cell Physiol. 2007;293:C584–596.CrossRefGoogle Scholar
  42. 42.
    Furukawa S et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Investig. 2004;114:1752–61.PubMedGoogle Scholar
  43. 43.
    Jacob S. Patient with beer belly or hypertension. Check for a metabolic syndrome! MMW Fortschr Med. 2005;147:45.PubMedGoogle Scholar
  44. 44.
    Reungjui S et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol. 2007;18:2724–31.PubMedCrossRefGoogle Scholar
  45. 45.
    Kodama S et al. Association Between Serum Uric Acid and Development of Type 2 Diabetes. Diabetes Care. 2009;32:1737–42.PubMedCrossRefGoogle Scholar
  46. 46.
    Alper AB et al. Childhood uric acid predicts adult blood pressure - The Bogalusa Heart Study. Hypertension. 2005;45:34–8.PubMedGoogle Scholar
  47. 47.
    Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. New Eng J Med. 1966;275:457–64.PubMedCrossRefGoogle Scholar
  48. 48.
    Turak O et al. Serum uric Acid, inflammation, and nondipping circadian pattern in essential hypertension. J Clin Hypertens. 2013;15:7–13.CrossRefGoogle Scholar
  49. 49.
    Lim KH, Friedman SA, Ecker JL, Kao L, Kilpatrick SJ. The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 1998;178:1067–71.PubMedCrossRefGoogle Scholar
  50. 50.
    Mazzali M et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Nakagawa T et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol. 2003;23:2–7.PubMedCrossRefGoogle Scholar
  52. 52.
    •• Kanbay M et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013. doi: 10.1136/heartjnl-2012-302535. This very good review article summarizes the emerging roles of uric acid in the pathogenesis of kidney disease,metabolic syndrome and diabetes and cardiovascular disease. All potential pathogenesis such as induction of oxidative stress, inflammation, endothelial dysfunction and activation of the rennin angiotensin aldosterone system were reviewed.
  53. 53.
    Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42:247–52.PubMedCrossRefGoogle Scholar
  54. 54.
    Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension—A randomized trial. JAMA. 2008;300:924–32.PubMedCrossRefGoogle Scholar
  55. 55.
    Gibson TJ. Hypertension, its treatment, hyperuricaemia and gout. Curr Opin Rheumatol. 2013;25:217–22.PubMedCrossRefGoogle Scholar
  56. 56.
    Haig A. On Uric Acid and Arterial Tension. Br Med J. 1889;1:288–91.PubMedCrossRefGoogle Scholar
  57. 57.
    Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis risk in communities (ARIC) study. Ann Epidemiol. 2000;10:136–43.PubMedCrossRefGoogle Scholar
  58. 58.
    Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol. 2001;87:1411–4.PubMedCrossRefGoogle Scholar
  59. 59.
    Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998;29:635–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB. Uric acid is a risk factor for myocardial infarction and stroke - The Rotterdam Study. Stroke. 2006;37:1503–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Okura T et al. Elevated Serum Uric Acid is an Independent Predictor for Cardiovascular Events in Patients With Severe Coronary Artery Stenosis - Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J. 2009;73:885–91.PubMedCrossRefGoogle Scholar
  62. 62.
    Madsen TE et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol. 2005;25:45–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum. 2009;61:225–32.PubMedCrossRefGoogle Scholar
  64. 64.
    Ndrepepa G et al. Prognostic value of uric acid in patients with acute coronary syndromes. Am J Cardiol. 2012;109:1260–5.PubMedCrossRefGoogle Scholar
  65. 65.
    Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med. 2005;2:e76.PubMedCrossRefGoogle Scholar
  66. 66.
    Kim SY et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62:170–80.Google Scholar
  67. 67.
    Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension. 1999;34:144–50.PubMedCrossRefGoogle Scholar
  68. 68.
    Anker SD et al. Uric acid and survival in chronic heart failure - Validation and application in metabolic, functional, and Hemodynamic staging. Circulation. 2003;107:1991–7.PubMedCrossRefGoogle Scholar
  69. 69.
    Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin. 2004;20:369–79.PubMedCrossRefGoogle Scholar
  70. 70.
    Cappola TP et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104:2407–11.PubMedCrossRefGoogle Scholar
  71. 71.
    George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508–16.PubMedCrossRefGoogle Scholar
  72. 72.
    Dahlof B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.PubMedCrossRefGoogle Scholar
  73. 73.
    Hoieggen A et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65:1041–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Kim SY et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009;61:885–92.PubMedCrossRefGoogle Scholar
  75. 75.
    Newman EJ, Rahman FS, Lees KR, Weir CJ, Walters MR. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. Diabetes Metabol Res Rev. 2006;22:79–82.CrossRefGoogle Scholar
  76. 76.
    Chamorro A et al. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke. 2002;33:1048–52.PubMedCrossRefGoogle Scholar
  77. 77.
    Leyva F et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18:858–65.PubMedCrossRefGoogle Scholar
  78. 78.
    Haig A. Uric acid as a factor in the causation of disease. London: J & A Churchill; 1897.Google Scholar
  79. 79.
    Berger L, Yu TF. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med. 1975;59:605–13.PubMedCrossRefGoogle Scholar
  80. 80.
    Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169:342–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Obermayr RP et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19:2008.CrossRefGoogle Scholar
  82. 82.
    • Iseki K et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691–7. This study with the large number of subjects (6,403) demonstrated that serum uric acid was a significant positive correlate of developing renal dysfunction in Japanese population. Google Scholar
  83. 83.
    Madero M et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53:796–803.PubMedCrossRefGoogle Scholar
  84. 84.
    Liu Y et al. The relationship between hyperuricemia and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with relatively normal serum creatinine. Clinics. 2013;68:19–25.PubMedCrossRefGoogle Scholar
  85. 85.
    • Helal I et al. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2012. doi: 10.1093/ndt/gfs417.Google Scholar
  86. 86.
    Kotsis V. S. S., Bouldin M, Low A, Toumanidis S, Zakopoulos N. Impact of obesity on 24-h ambulatory blood pressure and hypertension. Hypertension. 2005;45:602–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Kang DH et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888–97.PubMedCrossRefGoogle Scholar
  88. 88.
    Mazzali M et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. AmJ Physiol Ren Physiol. 2002;282:F991–997.Google Scholar
  89. 89.
    Kim SM et al. Reducing Serum Uric Acid Attenuates TGF-beta(1)-Induced Profibrogenic Progression in Type 2 Diabetic Nephropathy. Nephron Exp Nephrol. 2013;121:e108–20.Google Scholar
  90. 90.
    • Terawaki H et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study. Clinical and Exp Nephrol. 2012. doi: 10.1007/s10157-012-0742-z. This study shows that the use of allopurinol in hypertensive patients withkidney dysfunction seems to be beneficial in preventing cardiovascular morbidity and all-cause mortality.
  91. 91.
    • Miao Y et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58:2–7. This study supports that renoprotective effect of losrtan could partially be due to reduction of serum uric acid level. Losartan lowers uric acid levels compared with placebo treatment in patients with type 2 diabetes mellitus and nephropathy. These findings suggest that uric acid may be a modifiable risk factor for kidney disease. Google Scholar
  92. 92.
    Marriott BP, Cole N, Lee E. National estimates of dietary fructose intake increased from 1977 to 2004 in the United States. J Nutr. 2009;139:1228S–35S.PubMedCrossRefGoogle Scholar
  93. 93.
    Johnson RJ et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007;86:899–906.PubMedGoogle Scholar
  94. 94.
    Schulze MB et al. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA. 2004;292:927–34.PubMedCrossRefGoogle Scholar
  95. 95.
    Gersch MS et al. Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Ren Physiol. 2007;293:F1256–1261.CrossRefGoogle Scholar
  96. 96.
    Shoham DA et al. Sugary soda consumption and albuminuria: results from the National Health and Nutrition Examination Survey, 1999–2004. PLoS One. 2008;3:e3431.PubMedCrossRefGoogle Scholar
  97. 97.
    • Brymora A et al. Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease. Nephrol Dial Transplan. 2012;27:608–12. This clinical study shows the importance of low fructose diet in reduction of inflammation in patients with chronic kidney disease. Google Scholar
  98. 98.
    Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–41.PubMedCrossRefGoogle Scholar
  99. 99.
    Perez-Pozo SE et al. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. Int J Obes. 2010;34:454–61.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York (outside the USA) 2013

Authors and Affiliations

  • Zohreh Soltani
    • 1
    Email author
  • Kashaf Rasheed
    • 1
  • Daniel R. Kapusta
    • 2
  • Efrain Reisin
    • 1
  1. 1.Section of Nephrology and HypertensionLouisiana State University Health Sciences CenterNew OrleansUSA
  2. 2.Department of PharmacologyLouisiana State University Health Sciences CenterNew OrleansUSA

Personalised recommendations